Spots Global Cancer Trial Database for dexamethasone
Every month we try and update this database with for dexamethasone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02477215 | Multiple Myelom... | MLN9708 Dexamethasone Bendamustine (m... Bendamustine (M... | 18 Years - | Medical College of Wisconsin | |
| DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | NCT00083681 | Multiple Myelom... | Thalidomide Dexamethasone Cytoxan Etoposide Cisplatin G-CSF | 18 Years - | University of Arkansas | |
| Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00090909 | Lymphoma | cisplatin dexamethasone gemcitabine hyd... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00335140 | Lymphoma | Rituximab Cytarabine Dexamethasone Leucovorin Methotrexate Procarbazine Vincristine | 18 Years - | Eastern Cooperative Oncology Group | |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia | NCT01331590 | Precursor Cell ... | G-CSF Ifosfamide Etoposide Dexamethasone Mesna | 18 Years - | Washington University School of Medicine | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | NCT06136624 | Prostate Cancer... | Opevesostat Abiraterone ace... Enzalutamide Hydrocortisone Fludrocortisone... Prednisone Dexamethasone | - | Merck Sharp & Dohme LLC | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate | NCT00084864 | Prostate Cancer | calcitriol dexamethasone clinical observ... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | NCT00492999 | Colorectal Canc... Metastatic Canc... | dexamethasone floxuridine fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels | NCT01811199 | Thyroid Cancer Breast Cancer | 18 Years - 65 Years | Marmara University | ||
| Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | NCT02204241 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 65 Years - | Stichting European Myeloma Network | |
| Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer | NCT00002689 | Pancreatic Canc... | dexamethasone fluorouracil brachytherapy phosphorus P32 radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | NCT00579501 | Liposarcoma,Myx... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | NCT02243124 | Myelodysplastic... | cenersen Dexamethasone | 18 Years - 95 Years | Eleos, Inc. | |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | NCT02648490 | Solid Tumour | HLX07 Acetaminophen dexamethasone diphenhydramine 5-HT3 inhibitor | 18 Years - | Henlix, Inc | |
| Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01946152 | Multiple Myelom... Recurrent Plasm... Refractory Plas... | Dexamethasone Filgrastim-sndz Laboratory Biom... Pomalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT01348919 | Multiple Myelom... | CEP-18770 Lenalidomide Dexamethasone | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | NCT00319865 | Multiple Myelom... | Velcade Thalidomide Adriamycin Dexamethasone | 0 Years - 75 Years | Korean Multiple Myeloma Working Party | |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | NCT03719105 | NK-Cell Lymphom... NK-Cell Leukemi... Peripheral T Ce... | Methotrexate pralatraxate, Ifosfamide Dexamethasone Etoposide calaspargase pe... cyclophosphamid... Doxorubicin Prednisone Brentuximab Ved... | 1 Year - 31 Years | New York Medical College | |
| Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer | NCT01046461 | Solid Tumour Postoperative N... | Ramosetron, Apr... | 18 Years - 75 Years | Hallym University Medical Center | |
| Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer | NCT01698281 | Breast Cancer | AEZS-108 SCCC Dexamethasone | 18 Years - | AEterna Zentaris | |
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | NCT03252600 | Recurrent Prima... | Cyclophosphamid... Dexamethasone Elotuzumab Laboratory Biom... Lenalidomide Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | NCT01451515 | Lymphoblastic L... | Prednisone Vincristine Daunorubicin PEG-asparaginas... Erwinia asparag... Doxorubicin Cyclophosphamid... Cytarabine Thioguanine Clofarabine Methotrexate Mercaptopurine Dexamethasone Hydrocortisone Etoposide | - 21 Years | St. Jude Children's Research Hospital | |
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | NCT02586038 | Multiple Myelom... | MLN9708 Dexamethasone Cyclophosphamid... Thalidomide | 65 Years - | University of Turin, Italy | |
| Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia | NCT00777738 | Waldenstrom Mac... | BORTEZOMIB | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | NCT06210750 | T Acute Lymphob... T Lymphoblastic... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | NCT00002785 | Leukemia | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine mesna methotrexate methylprednisol... pegaspargase prednisone therapeutic hyd... vincristine sul... allogeneic bone... low-LET cobalt-... low-LET photon ... | - 1 Year | Children's Oncology Group | |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | NCT01054144 | Multiple Myelom... | Lenalidomide Prednisone Dexamethasone | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery | NCT03172988 | Carcinoma, Non-... Surgery Dexamethasone Flubiprofen Axe... Long-term Effec... | Dexamethasone Normal saline Flurbiprofen ax... Lipid microsphe... | 18 Years - 85 Years | Peking University First Hospital | |
| Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy | NCT00152867 | Cancer Emesis Nausea | Dexamethasone | 18 Years - | University Health Network, Toronto | |
| A Study in Adults With Untreated Acute Lymphoblastic Leukemia | NCT00136435 | Acute Lymphobla... | prednisone doxorubicin vincristine methotrexate asparaginase dexamethasone cranial radiati... leucovorin cytarabine hydrocortisone 6-mercaptopurin... e. coli L-aspar... | 18 Years - 50 Years | Dana-Farber Cancer Institute | |
| Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer | NCT01748942 | Dysphagia Pain Stage I Orophar... Stage II Oropha... Stage III Oroph... | Dexamethasone Dexamethasone Placebo Quality-of-Life... Questionnaire A... Transoral Robot... | 18 Years - | OHSU Knight Cancer Institute | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01527149 | Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle... | Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | 18 Years - 70 Years | Roswell Park Cancer Institute | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | NCT03104842 | Multiple Myelom... | Isatuximab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | NCT01794039 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | NCT03731832 | Refractory Mult... | MLN9708 Pomalidomide 4 ... Dexamethasone Cyclophosphamid... | 18 Years - | GWT-TUD GmbH | |
| XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors | NCT00088166 | Brain Edema Brain Tumor | hCRF placebo hCRF | 18 Years - | Celtic Pharma Development Services | |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) | NCT02955810 | Multiple Myelom... | Daratumumab Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 70 Years | National University of Ireland, Galway, Ireland | |
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients | NCT04503668 | Gynecologic Can... | Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine | 18 Years - 89 Years | University of Michigan Rogel Cancer Center | |
| Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | NCT01159574 | Multiple Myelom... | dexamethasone clarithromycin Pomalidomide | 18 Years - | Weill Medical College of Cornell University | |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) | NCT06136598 | Prostatic Neopl... Metastatic Cast... | Opevesostat Dexamethasone Fludrocortisone Hydrocortisone | 18 Years - | Merck Sharp & Dohme LLC | |
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | NCT00807599 | Multiple Myelom... | Stem cell trans... lenalidomide an... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects | NCT01980589 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 18 Years - | Amgen | |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | NCT05289492 | Multiple Myelom... | EOS884448 Iberdomide Dexamethasone | 18 Years - | iTeos Therapeutics | |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | NCT05288062 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas... | Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone | NCT03180736 | Multiple Myelom... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Stichting European Myeloma Network | |
| Hepatic Artery Infusion Pump for NPC Liver Metastases | NCT03876574 | Nasopharyngeal ... Neoplasm Metast... Liver | DSA-guided impl... Gemcitabine Floxuridine dexamethasone | - | Xiangya Hospital of Central South University | |
| Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | NCT00718757 | Non-Hodgkins Ly... Hodgkin's Disea... Acute Lymphobla... | Dexamethasone Irinotecan Vincristine | - 21 Years | St. Jude Children's Research Hospital | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | NCT00408005 | T Acute Lymphob... T Lymphoblastic... | Asparaginase Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Nelarabine Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 30 Years | National Cancer Institute (NCI) | |
| Dexamethasone for Post Uterine Artery Embolization Pain | NCT04655144 | Leiomyoma | Dexamethasone Saline | 20 Years - 50 Years | University of Miami | |
| Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00564889 | Multiple Myelom... | cyclophosphamid... dexamethasone lenalidomide | 18 Years - | Mayo Clinic | |
| MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning | NCT00564200 | Multiple Myelom... | Bortezomib dexamethasone Fludarabine Melphalan | 18 Years - 66 Years | PETHEMA Foundation | |
| Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | NCT00559481 | Prostate Cancer | dexamethasone ketoconazole therapeutic hyd... pharmacological... | - | Roswell Park Cancer Institute | |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | NCT00005987 | Multiple Myelom... | carmustine cyclophosphamid... dexamethasone etoposide filgrastim mitoxantrone hy... recombinant int... sargramostim bone marrow abl... peripheral bloo... radiation thera... | - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | NCT00200200 | Hepatic Metasta... Colon Cancer Rectal Cancer | Bevacizumab HAI... HAI plus system... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00238225 | Unspecified Adu... | calcitriol dexamethasone ketoconazole | 18 Years - | Roswell Park Cancer Institute | |
| Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma | NCT00275106 | Lymphoma | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone doxorubicin hyd... leucovorin calc... mercaptopurine methotrexate prednisolone thioguanine vincristine sul... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT01217957 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | NCT01381692 | Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... | Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | NCT05405166 | Plasma Cell Mye... | Isatuximab IV Isatuximab SC Dexamethasone Pomalyst or equ... | 18 Years - | Sanofi | |
| Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | NCT00381680 | B-cell Childhoo... L1 Childhood Ac... L2 Childhood Ac... Intermediate Ri... | vincristine sul... prednisone doxorubicin hyd... pegaspargase cytarabine methotrexate dexamethasone etoposide cyclophosphamid... leucovorin calc... filgrastim asparaginase mercaptopurine | 1 Year - 29 Years | Children's Oncology Group | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
